IDOV-Safe / ViroMissile - LARVOL DELTA

Intravenous oncolytic virus IDOV-Safe in pMMR/MSS metastatic colorectal cancer. (ASCO 2026) - P1 | "Intravenous IDOV-Safe demonstrated a favorable safety profile and encouraging preliminary antitumor activity when combined with toripalimab and fruquintinib, particularly using a sequential combination strategy in heavily pretreated patients with pMMR/MSS mCRC. Response to IDOV-safe and immuno-targeted therapy. *One patient in IIA2 cohort had unconfirmed SD."

Metastases • Oncolytic virus • pMMR • Colorectal Cancer • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (clinicaltrials.gov) - P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

IO biomarker • New P1/2 trial • Oncology • Solid Tumor

LY001-I001: A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE (clinicaltrials.gov) - P1 | N=89 | Recruiting | Sponsor: Peking University | N=60 ➔ 89

Enrollment change • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor